9
Participants
Start Date
September 18, 2023
Primary Completion Date
March 18, 2025
Study Completion Date
March 18, 2026
anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
"Each subject will be infused with single dose. A classic 3+3 dose escalation will be employed.~anti-CD19-CAR T-cells~Dose level 1:1x10\^5 CAR T cells/kg, Dose level 2:3x10\^5 CAR T cells/kg, Dose level 3:1x10\^6 CAR T cells/kg~anti-CD30-CAR T-cells~Dose level 1:3x10\^6 CAR T cells/kg, Dose level 2:6x10\^6 CAR T cells/kg, Dose level 3:1x10\^7 CAR T cells/kg~anti-CD20/CD30-CAR T-cells~Dose level 1:1x10\^6 CAR T cells/kg, Dose level 2:3x10\^6 CAR T cells/kg, Dose level 3:1x10\^7 CAR T cells/kg"
Fludarabine
Fludarabine will be given at a dose of 25 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
Cyclophosphamide
Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
RECRUITING
Affiliated Hospital of Nantong University, Nantong
Shanghai First Song Biotechnology Co., LTD
INDUSTRY
Affiliated Hospital of Nantong University
OTHER